Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04662801 · ClinicalTrials.gov registry record · Phase 2

Weight Regain Treatment Post-Bariatric Surgery

A Phase 2 study of Obesity & Overweight, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
26
Enrollment target
1
Study location

NCT04662801 is a Phase 2 study of Obesity & Overweight that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 127-participant average among 15 other Obesity & Overweight trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04662801, a Phase 2 study of Obesity & Overweight, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.

Conditions Studied

Interventions

  • BEHAVIORAL Behavioral Weight Loss (BWL)
  • BEHAVIORAL Early Responder: BWL continued
  • COMBINATION_PRODUCT Early Non-responder: BWL continued with medication added

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2021-08-05
Est. Completion 2022-09-13
Phase Phase 2

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04662801

The ClinicalTrials.gov registry entry for NCT04662801 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 127-participant average among 15 other Obesity & Overweight trials with a reported enrollment target (80% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity & Overweight appearing as the primary indexed condition, and to 3 interventions - of which Behavioral Weight Loss (BWL) is the first listed.

NCT04662801 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT04662801 about?

NCT04662801 is a clinical study titled "Weight Regain Treatment Post-Bariatric Surgery". This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.

What is the current status of trial NCT04662801?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-08-05. Estimated completion is 2022-09-13.

What conditions does trial NCT04662801 study?

This clinical trial studies the following conditions: Obesity & Overweight.

What interventions are being tested in trial NCT04662801?

The interventions under investigation include: Behavioral Weight Loss (BWL) (BEHAVIORAL), Early Responder: BWL continued (BEHAVIORAL), Early Non-responder: BWL continued with medication added (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT04662801?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04662801 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity & Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.